Browsing by Author Xu, Jianfeng

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)
2014Association analysis identifies new risk loci for non-obstructive azoospermia in Chinese menHu, Zhibin; Li, Zheng; Yu, Jun; Tong, Chao; Lin, Yuan; Guo, Xuejiang; Lu, Feng; Dong, Jing; Xia, Yankai; Wen, Yang; Wu, Hao; Li, Honggang; Zhu, Yong; Ping, Ping; Chen, Xiangfeng; Dai, Juncheng; Jiang, Yue; Pan, Shandong; Xu, Peng; Luo, Kailing; Du, Qiang; Yao, Bing; Liang, Ming; Gui, Yaoting; Weng, Ning; Lu, Hui; Wang, Zhuqing; Zhang, Fengbin; Zhu, Xiaobin; Yang, Xiaoyu; Zhang, Zhou; Zhao, Han; Xiong, Chenliang; Ma, Hongxia; Jin, Guangfu; Chen, Feng; Xu, Jianfeng; Wang, Xinru; Zhou, Zuomin; Chen, Zi-Jiang; Liu, Jiayin; Shen, Hongbing; Sha, Jiahao
2012Association of 8q22.3 locus in Chinese Han with idiopathic premature ovarian failure (POF)Qin, Yingying; Zhao, Han; Xu, Jianfeng; Shi, Yongyong; Li, Zhiqiang; Qiao, Jie; Liu, Jiayin; Qin, Chunrong; Ren, Chune; Li, Jie; Chen, Shiling; Cao, Yunxia; Simpson, Joe Leigh; Chen, Zi-Jiang
2006Cellular effects and metabolic stability of N1-cyclic inosine diphosphoribose and its derivativesKirchberger, Tanja; Wagner, Gerd; Xu, Jianfeng; Wang, Pei; Gassers, Andreas; Fliegert, Ralf; Bruhn, Soeren; Lund, Frances E.; Zhang, Li-he; Potter, Barry V. L.; Guse, Andreas H.
15-Nov-2022Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) TrialOpat, Stephen; Tedeschi, Alessandra; Hu, Bei; Linton, Kim M.; McKay, Pamela; Chan, Henry; Jin, Jie; Sun, Mingyuan; Sobieraj-Teague, Magdalena; Zinzani, Pier Luigi; Browett, Peter J.; Ke, Xiaoyan; Portell, Craig A.; Thieblemont, Catherine; Ardeshna, Kirit; Bijou, Fontanet; Walker, Patricia; Hawkes, Eliza; Ho, Shir-Jing; Zhou, Keshu; Liang, Zhiyu; Xu, Jianfeng; Tankersley, Chris; Delarue, Richard; Co, Melannie; Trotman, Judith
Feb-2020A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFN alpha therapy in Chinese HBeAg-positive chronic hepatitis B patientsChen, Haitao; Sun, Jian; Zhou, Bin; Peng, Jinxin; Xie, Qing; Liang, Xieer; Fan, Rong; Conran, Carly; Xu, Jianfeng; Ji, Yuan; Zhang, Xinxin; Sun, Li; Jia, Jidong; Wang, Guiqiang; Hou, Jinlin; Jiang, De-Ke
Sep-2022Requirements of Scintillation Crystals with the Development of PET ScannersYu, Xin; Zhang, Xi; Zhang, Heng; Peng, Hao; Ren, Qiushi; Xu, Jianfeng; Peng, Qiyu; Xie, Siwei
2014Response and Adaptation of Escherichia coli to Suppression of the Amber Stop CodonWang, Qian; Sun, Tingting; Xu, Jianfeng; Shen, Zhouxin; Briggs, Steven P.; Zhou, Demin; Wang, Lei
2006Synthesis and agonist activity of cyclic ADP-ribose analogues with substitution of the northern ribose by ether or alkane chainsXu, Jianfeng; Yang, Zhenjun; Dammermann, Werner; Zhang, Liangren; Guse, Andreas H.; Zhang, Li-he
Nov-2020Unexpected HbA(1c) results in the presence of three rare hemoglobin variantsXu, Jianfeng; Zhong, Zhijuan; Deng, Yukui
Jan-2020Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alphaChen, Haitao; Sun, Jian; Zhou, Bin; Xie, Qing; Liang, Xier; Fan, Rong; Conran, Carly; Xu, Jianfeng; Ji, Yuan; Zhang, Xinxin; Sun, Li; Jia, Jidong; Wang, Guiqiang; Hou, Jinlin; Jiang, De-Ke